Table 1 Subject characteristics

Longitudinal clinical diagnosis

1 CN to MCI

1 MCI stable

1 MCI to DAT

2 MCI to DAT

-

2 MCI stable

3 MCI to DAT

1 DAT

5 DAT

2 DAT

2 MCI to DAT

2 DAT

Neuropathological diagnosis

1 LNC AD

1HNC AD + MTL-TDP

1 HNC AD + DLB

1 DLB-LNC

-

3 HNC AD

AD + AGD

3 HNC AD + SVD-I

2 LNC AD + AGD + MTL-TDP

3 HNC

1 DLB- LNC AD + MTL-TDP

2 HNC AD + DLB + MTL-TDP

1HNC AD + AGD + MTL-TDP + HS

1HNC AD + AGD + MTL-TDP + HS + SVD-I

AD- + DLB

1 HNC AD-DLB + SVD-I

1 DLB + LNC AD

Age at death (years) ²

80 (77–83)

86 (82–88)

80.5 (72.25-83.75)

81 (77.75-84.75)

0.41

Gender (n male/total)

3/7

4/5

6/6

4/4

1.0

Education (years) ¹

15.4 (2.4)

15.0 (2.4)

16.1 (2.6)

14.0 (2.3)

0.62

Baseline visit to death (weeks) ²

240.7 (98.7-256.8)

181.9 (108.4-289.0)

136.5 (80.9-278.3)

234.9 (189.1-257.1)

0.72

APOE ϵ4 (n positive/total)

4/7

1/5

5/6

1/3

0.18

ADAS-Cog (13 item) baseline ²

20.0 (10.3-28.0)

22.0 (17.7-29.0)

33.3 (18.0-54.7)

30.3 (25.3-35.0)

0.041

Aβ_1-42 (pg/mL) ²

134.0 (86.0-261.0)

249.0 (123.0-261.0)

138.0 (82.0-152.0)

171.0 (134.0-201.9)

0.59

T-Tau (pg/mL) ²

141.5 (60.0-274.0)

65.0 (55.0-89.0)

88.0 (37.0-154.0)

73.0 (56.0-103.6)

0.61

P-Tau₁₈₁ (pg/mL) ²

51.0 (17.0-70.0)

22.0 (12.0-33.0)

28.0 (11.0-45.0)

21.0 (19.0-24.0)

0.32